US2023092021A1PendingUtilityA1

Bacteriophage compositions for treating staphylococcus infection

67
Assignee: ARMATA PHARMACEUTICALS INCPriority: Feb 18, 2020Filed: Aug 16, 2022Published: Mar 23, 2023
Est. expiryFeb 18, 2040(~13.6 yrs left)· nominal 20-yr term from priority
Inventors:Stacey Lynn KolarBrian Varnum
C12N 7/00A61K 35/76A61P 31/04A61K 38/00A61K 45/06C12N 2795/10132A61K 9/0078A61K 9/0019
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to bacteriophages and compositions capable of infecting and killing Staphylococcus, and use of the same for treating Staphylococcus, e.g. Staphylococcus aureus, bacterial infections.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1. 
     
     
         3 . (canceled) 
     
     
         4 . An isolated, purified bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2. 
     
     
         5 . The bacteriophage of  claim 2 , wherein the bacteriophage is resistant to blood complement inactivation. 
     
     
         6 . A bacteriophage composition comprising one or more bacteriophage selected from a bacteriophage comprising a polynucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2. 
     
     
         7 . (canceled) 
     
     
         8 . The bacteriophage composition of  claim 6 , wherein the bacteriophage infect and kill  Staphylococcus aureus.    
     
     
         9 . The bacteriophage composition of  claim 6 , further comprising a storage media for storage at a temperature at or below 8° C. 
     
     
         10 . The bacteriophage composition of  claim 6 , wherein the bacteriophage is resistant to blood complement inactivation. 
     
     
         11 . The bacteriophage composition of  claim 6 , wherein the one or more bacteriophage belong to the genus Silviavirus. 
     
     
         12 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1. 
     
     
         13 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1. 
     
     
         14 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2. 
     
     
         15 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 2. 
     
     
         16 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1 and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2. 
     
     
         17 . The composition of  claim 6 , wherein the composition comprises a bacteriophage comprising the polynucleotide sequence of SEQ ID NO: 1 and a bacteriophage having a genome comprising the polynucleotide sequence of SEQ ID NO: 2. 
     
     
         18 . The bacteriophage composition of  claim 6 , wherein the composition is substantially free of a bacterial component. 
     
     
         19 . The composition of  claim 18 , wherein the bacterial component comprises bacterial host protein. 
     
     
         20 . The composition of  claim 6 , wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof. 
     
     
         21 . The composition of  claim 6 , wherein the composition is a liquid, semi-liquid, solid, frozen, or lyophilized formulation. 
     
     
         22 . The composition of  claim 6 , wherein the bacteriophages of the composition target one or more of vancomycin-intermediate  Staphylococcus aureus  (VISA), vancomycin-resistant  Staphylococcus aureus  (VRSA), methicillin-resistant (MRSA)  Staphylococcus aureus.    
     
     
         23 . The composition of  claim 22 , wherein the bacteriophages infect and kill one or more of vancomycin-intermediate  Staphylococcus aureus  (VISA), vancomycin-resistant  Staphylococcus aureus  (VRSA), methicillin-resistant  Staphylococcus aureus  (MRSA). 
     
     
         24 . The composition of  claim 6 , wherein the composition comprises between 1×10 8  and 1×10 11  PFU of each bacteriophage. 
     
     
         25 . The composition of  claim 6 , wherein the composition is to be administered at a dosage of at least 1×10 9  PFU of total bacteriophages per milliliter. 
     
     
         26 . The composition of  claim 6 , wherein the composition is stored at 2-8° C. 
     
     
         27 . The composition of  claim 6 , wherein at least one bacteriophage is obligately lytic. 
     
     
         28 . The bacteriophage of  claim 1 , wherein the sequence of at least one bacteriophage is genetically modified. 
     
     
         29 . A method of treating a bacterial infection comprising administering the bacteriophage of  claim 1  to a subject in need of treatment. 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . A bacterial host manufacturing strain comprising a bacteriophage wherein said bacteriophage comprises a polynucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, a polynucleotide sequence with at least 90% identity to SEQ ID NO: 1, and a polynucleotide sequence with at least 90% identity to SEQ ID NO: 2. 
     
     
         34 . A method of treating a subject with a bacterial infection comprising selecting a bacteriophage based upon resistance to blood complement inactivation and administering said bacteriophage to the subject. 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . The composition of  claim 6 , wherein the composition is formulated for administration to a subject with a bacterial infection. 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . The composition of  claim 6 , wherein the composition is formulated for administration to a subject to target  Staphylococcus aureus  bacteria. 
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . (canceled) 
     
     
         45 . (canceled) 
     
     
         46 . (canceled) 
     
     
         47 . (canceled) 
     
     
         48 . (canceled) 
     
     
         49 . (canceled) 
     
     
         50 . (canceled) 
     
     
         51 . (canceled) 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . (canceled) 
     
     
         55 . (canceled) 
     
     
         56 . (canceled) 
     
     
         57 . (canceled) 
     
     
         58 . (canceled) 
     
     
         59 . (canceled) 
     
     
         60 . (canceled) 
     
     
         61 . The composition of  claim 6 , wherein the composition is administered intravenously, via intra-articular injection, via inhalation, or via nebulization. 
     
     
         62 . (canceled) 
     
     
         63 . (canceled) 
     
     
         64 . (canceled) 
     
     
         65 . (canceled) 
     
     
         66 . (canceled) 
     
     
         67 . (canceled) 
     
     
         68 . (canceled) 
     
     
         69 . (canceled)

Join the waitlist — get patent alerts

Track US2023092021A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.